The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses cancer patients with brain metastases, who have historically been excluded from clinical trials, how this has changed, and criteria that make brain metastases clinical trials unique.
Tags: Brain (includes Glioblastoma Multiforme, Glioma, Brain Mets)SNO Conference
Published: 24 August 2020
Matthew Dankner considers how CIRBP pathway might be targetable and the status of the research
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, considers how the cold-inducible RNA binding protein (CIRBP) pathway might be targetable and the status of the research leading to potential clinical application.
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, considers how the cold-inducible RNA binding protein (CIRBP) pathway ...
Matthew Dankner explains how CIRBP was identified as important to invasive cells in brain metastases
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, explains how Cold-inducible RNA binding protein (CIRBP) was identified as important to the growth of highly invasive cells in brain metastases.
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, explains how Cold-inducible RNA binding protein (CIRBP) was identified ...
Matthew Dankner describes a double blinded analysis of 164 brain metastases patients characterized by minimally or highly invasive characteristics
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes a double blinded analysis of 164 brain metastases patients characterized by minimally or highly invasive characteristics supporting the principle of invasive histopathology, the risk of local recurrence, and the impact on survival.
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes a double blinded analysis of 164 brain metastases ...
Matthew Dankner describes how the concept of invasive histopathology relates to brain metastases
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes how the concept of invasive histopathology provides an alternative theory to the spilling of cancer cells and the recurrence of brain metastases after resection
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes how the concept of invasive histopathology provides an ...
David Roberge, MD, examines why individuals may prefer SRS while others may would opt for WBRT
Dr. Roberge, Head of Radiation Oncology, University of Montreal, examines why individuals may prefer stereotactic radiotherapy (SRS) while others may would opt for whole brain radiation treatment (WBRT).
Dr. Roberge, Head of Radiation Oncology, University of Montreal, examines why individuals may prefer stereotactic radiotherapy (SRS) while others may ...
David Roberge, MD, discusses how COVID-19 affected enrollment in the CE.7 clinical trial
Dr. Roberge, Head of Radiation Oncology, University of Montreal, discusses how COVID-19 affected enrollment in the CE.7 clinical trial, how the trial was amended, and expectations for how COVID-19 will impact the completion of the trial.
Dr. Roberge, Head of Radiation Oncology, University of Montreal, discusses how COVID-19 affected enrollment in the CE.7 clinical trial, how ...
David Roberge, MD, explains rationale for the design of the CE.7 trial
Dr. Roberge, Head of Radiation Oncology, University of Montreal, explains rationale for the design of the CE.7 trial requiring both hippocampal avoidance and treatment with memantine in the WBRT arm and why it may be relevant to coprimary endpoint and secondary endpoints.
Dr. Roberge, Head of Radiation Oncology, University of Montreal, explains rationale for the design of the CE.7 trial requiring both ...
David Roberge, MD, describes rationale for cross-border CE.7 trial in patients with brain metastases
Dr. Roberge, Head of Radiation Oncology, University of Montreal, describes the rationale for the cross-border CE.7 trial enrolling patients with 5 or more brain metastases compared to numerous trials comparing stereotactic radiotherapy (SRS) to whole brain radiation treatment (WBRT) with patients with four or fewer brain metastases.
Dr. Roberge, Head of Radiation Oncology, University of Montreal, describes the rationale for the cross-border CE.7 trial enrolling patients with ...
Raymond Sawaya, MD, considers definitive clinical trial outcomes and non-invasive treatment
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, considers the definitive clinical trial outcomes in certain cancer types and the application of non-invasive treatment for brain metastases.
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, considers the definitive clinical trial outcomes in ...
Raymond Sawaya, MD, discusses the addition of patients with brain metastases to clinical trials
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses cancer patients with brain metastases, who have historically been excluded from clinical trials, how this has changed, and criteria that make brain metastases clinical trials unique.
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses cancer patients with brain metastases, who ...
Matthew Dankner considers how CIRBP pathway might be targetable and the status of the research
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, considers how the cold-inducible RNA binding protein (CIRBP) pathway might be targetable and the status of the research leading to potential clinical application.
Matthew Dankner explains how CIRBP was identified as important to invasive cells in brain metastases
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, explains how Cold-inducible RNA binding protein (CIRBP) was identified as important to the growth of highly invasive cells in brain metastases.
Matthew Dankner describes a double blinded analysis of 164 brain metastases patients characterized by minimally or highly invasive characteristics
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes a double blinded analysis of 164 brain metastases patients characterized by minimally or highly invasive characteristics supporting the principle of invasive histopathology, the risk of local recurrence, and the impact on survival.
Matthew Dankner describes how the concept of invasive histopathology relates to brain metastases
Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes how the concept of invasive histopathology provides an alternative theory to the spilling of cancer cells and the recurrence of brain metastases after resection
David Roberge, MD, examines why individuals may prefer SRS while others may would opt for WBRT
Dr. Roberge, Head of Radiation Oncology, University of Montreal, examines why individuals may prefer stereotactic radiotherapy (SRS) while others may would opt for whole brain radiation treatment (WBRT).
David Roberge, MD, discusses how COVID-19 affected enrollment in the CE.7 clinical trial
Dr. Roberge, Head of Radiation Oncology, University of Montreal, discusses how COVID-19 affected enrollment in the CE.7 clinical trial, how the trial was amended, and expectations for how COVID-19 will impact the completion of the trial.
David Roberge, MD, explains rationale for the design of the CE.7 trial
Dr. Roberge, Head of Radiation Oncology, University of Montreal, explains rationale for the design of the CE.7 trial requiring both hippocampal avoidance and treatment with memantine in the WBRT arm and why it may be relevant to coprimary endpoint and secondary endpoints.
David Roberge, MD, describes rationale for cross-border CE.7 trial in patients with brain metastases
Dr. Roberge, Head of Radiation Oncology, University of Montreal, describes the rationale for the cross-border CE.7 trial enrolling patients with 5 or more brain metastases compared to numerous trials comparing stereotactic radiotherapy (SRS) to whole brain radiation treatment (WBRT) with patients with four or fewer brain metastases.
Raymond Sawaya, MD, considers definitive clinical trial outcomes and non-invasive treatment
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, considers the definitive clinical trial outcomes in certain cancer types and the application of non-invasive treatment for brain metastases.
Raymond Sawaya, MD, on treating brain metastases with stereotactic radiotherapy prior to resection
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, explains the rationale for treating brain metastases with stereotactic radiotherapy prior to resection as suggested at the SNO Virtual Conference.
Raymond Sawaya, MD, identifies non-invasive ways of treating brain metastases and possible outcomes
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, identifies non-invasive ways of treating brain metastases and the possible advantages and disadvantages of each.
Raymond Sawaya, MD, discusses whether it is advisable to obtain brain scans at early stages of care
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses whether it is advisable, or even essential, to obtain brain scans at early stages as a strategy to identify lesions when they remain small in cancers associated with a high risk of brain metastases.
Raymond Sawaya, MD, shares the incidence and severity of brain metastases amongst cancer patients
Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, shares the incidence and severity of brain metastases amongst cancer patients and the concern for physicians treating patients.
Nader Sanai, MD, on the role of ribociclib in the management of gliomas
Dr. Sanai, Department of Neurosurgery, Director, Ivy Brain Tumor Center, on the role of Kisqali (ribociclib) in the management of gliomas
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.